FindTrial
Sign In

A retrospective study of anti-tumor immunotherapy related liver injury

A retrospective study of anti-tumor immunotherapy related liver injury

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300067470
Enrollment
Unknown
Registered
2023-01-09
Start date
2023-01-09
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver injury

Interventions

Observation group:None

Sponsors

Zhongshan Hospital,Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 82/5000 ? From January 2019 to June 2022, he was treated in Zhongshan Hospital Affiliated to Fudan University ? over 18 years old ? Malignant tumors with definite clinical and histopathological diagnosis ? At least one cycle of treatment with any immune checkpoint inhibitor has been performed

Exclusion criteria

Exclusion criteria: ? The antitumor therapy received was an unblinded clinical trial protocol, and the type of treatment could not be determined ? The lack of liver function and other key clinical data is incomplete, which can not make clinical judgment for the diagnosis of ICIS-related liver injury

Design outcomes

Primary

MeasureTime frame
Liver function;ALT;AST;TB;GGT;AKP;ALB;PT;—

Countries

China

Contacts

Public ContactZhang Ningping

Zhongshan Hospital, Fudan University

zhang.ningping@zs-hospital.sh.cn13916716151

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026